Наверх

News

Politics

08.05.2008

House of Representatives ratifies Belarusian-Russian drug agreement

On May 14, 2008 a plenary meeting of Permanent Commission on International Affairs and Relations with CIS of the House of Representatives of the National Assembly of the Republic of Belarus is taking place, in the course of which the bill about ratification of Belarusian-Russian agreement on cooperation development in the sphere of industry and reciprocal drug deliveries is planned to be considered. That was said to the www.soyuz.by correspondent in the press service of Lower Chamber of Belarusian Parliament.

On May 14, 2008 a plenary meeting of Permanent Commission on International Affairs and Relations with CIS of the House of Representatives of the National Assembly of the Republic of Belarus is taking place, in the course of which the bill about ratification of Belarusian-Russian agreement on cooperation development in the sphere of industry and reciprocal drug deliveries is planned to be considered. That was said to the www.soyuz.by correspondent in the press service of Lower Chamber of Belarusian Parliament.

Vasili Zharko, Minister of Health Care in Belarus, is supposed to report on the agreement.

Agreement on cooperation development in the sphere of industry and reciprocal drug deliveries was signed at the Supreme State Council meeting that took place in Minsk on December 14, 2007. The document implies the development and expansion of two-way trade and economic and scientific and technical communication in the sphere of industry and reciprocal drug deliveries, equal registration conditions arrangement and the realization of the Belarusian drugs on Russian market.

According to the agreement the parties will develop cooperation in the sphere of common drug production and its foreign market promotion. It is provided in the document that the licensing of the import of drugs produced in the state of the second party of the agreement won’t be applied. For state registration of drugs a fee at the rate set for producers is paid.

The parties reserve the right to provide restrictive measures in the relation to drugs that pose a threat to population health as well as the right to make extra production analyses and examinations.